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Abstract Anecdotal data in the last few years suggest
that protein-sparing modified diet (PSMF) delivered by
naso-gastric tube enteral (with continuous feeding) could
attain an significant weight loss and control of appetite oral
feeding, but no phase II studies on safety and efficacy have
been done up to now. To verify the safety and efficacy of a
protein-sparing modified fast administered by naso-gastric
tube (ProMoFasT) for 10 days followed by 20 days of a
low-calorie diet, in patients with morbid obesity (appetite
control, fat free mass maintenance, pulmonary function
tests and metabolic pattern, side effects), 26 patients with a
BMI C30 kg/m2 have been selected. The patients had to
follow a protein-sparing fast by enteral nutrition (ProMo-
FasT) for 24 h/day, for 10 days followed by 20 days of
low-calorie diet (LCD). The endpoint was represented by
body weight, BMI, abdominal circumference, Haber’s
appetite test, body composition by body impedance
assessment (BIA), handgrip strength test, metabolic pat-
tern, pulmonary function test. Safety was assessed by
evaluation of complications and side effects of PSMF and/
or enteral nutrition. In this report the results on safety and
efficacy are described after 10 and 30 days of treatment.
After the recruiting phase, a total of 22 patients out of 26
enrolled [14 (63.6 %) females] were evaluated in this
study. Globally almost all clinical parameters changed
significantly during first 10 days. Total body weight sig-
nificantly decreased after 10 days (D-6.1 ± 2; p \ 0.001)
and this decrease is maintained in the following 20 days of
LCD (D = -5.88 ± 1.79; p \ 0.001). Also the abdominal
circumference significantly decreased after 10 days [med-
ian (range): -4.5 (-30 to 0); p \ 0.001] maintained then
in the following 20 days of LCD [median (range) = -7
(-23.5 to -2); p \ 0.001]. All BIA parameters signifi-
cantly changed after 10 and 30 days from baseline. All
parameters except BF had a significant change after
10 days of treatment while the difference at 30 days was
lower than at 10 days for TBW, FFM and MM with no
significant differences from baseline for the last two
characteristics. For VAS appetite the difference was sig-
nificant after 10 days and the decrease in appetite was
maintained at 30 days with no significant difference
(p = 0.83) between 10 and 30 days. No significant differ-
ences in the first 30 days were detected for PA and for both
left and right hand grip strength. Particularly, a significant
reduction of 1.82 kg in FFM after 10 days was detected,
but not after 30 days. In contrast, a decrease of 3.8 kg of
BF is observed after 30 days. As far as the respiratory
functional tests (RFT) are concerned, a significant differ-
ence at 10 days was globally observed for functional
residual capacity (p = 0.012) and expiratory reserve vol-
ume (p = 0.025). There are no reported major complica-
tions and side effects resulting from the enteral nutrition or
PSMF. In particular, cardiac arrhythmias have not been
reported. From the clinical point of view the PSMF with
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naso-gastric tube (ProMoFasT) method appears safe, it is
associated with a significant weight loss related to decrease
of FM and not to loss of FFM and appetite decreases. It is
relevant that the RFT are significantly improved after only
10 days suggesting the efficacy of this regime in short
period, too. These preliminary data underline the necessity
to increase the number of RCT for this method, which
could represent a possible alternative to other methodolo-
gies, such as the intragastric balloon, in particular when it
is recommended to improve RFT before bariatric, gyne-
cological, orthopedic and lymphatic surgery.
Keywords VLCD  PSMF  Tube feeding  Enteral
nutrition  Protein  NEP  Ketogenic diet  Pulmonary
function test  Hand grip strength  Obesity  Appetite 
Enteral nutrition  Protein-sparing modified fasting
by tube  ProMoFasT
Introduction
The increase in obesity in western populations constitutes a
significant health problem and in countries like the US, the
prevalence is estimated to be about 18–20 %. In Italy,
overall prevalence of obesity is approximately 9 % while
the severe form affects 1 % of the population with a higher
incidence in females. Obesity (especially if moderate–
severe) creates significant morbility and mortality.
Currently available therapeutic strategies for the treat-
ment of obesity are dietetic-behavioral, pharmaceutical and
surgical.
The last option is usually adopted in patients with severe
obesity ([40 kg/m2) or with a BMI [35 kg/m2 and mul-
tiple related diseases, who are non-responders to the other
available options.
Also if in the recent years new methods have been
developed to obtain fast results before bariatric surgery,
there exists clinical situations in which it could be advo-
cated to reduce weight fastly [i.e., obese patients (BMI
30–45 kg/m2)], affected by comorbidities such as ortho-
pedic diseases (coxarthrosis, gonarthrosis), moderate or
severe respiratory (OSAS) diseases, patients that need to
loose weight quickly due to scheduled vascular or ortho-
pedic surgery and are not eligible for bariatric surgery for
esthetic or pneumological risk.
Even though intragastric balloon (IGB) is a possible
medical choice since it is associated with an improvement/
cure of the severe obesity, according to a recent cochrane,
it is absolutely contraindicated in case of voluminous hiatal
hernia, abnormalities of the pharynx and oesophagus,
oesophagus varicose veins, use of anti-inflammatory or
anti-coagulant drugs, pregnancy and psychiatric disorders
[1]. Relative contraindications are oesophagitis, ulceration
and acute lesions of the gastric mucous membrane [1].
Comparing IGB with conventional management, there is
not convincing evidence of a greater weight loss [1].
Moreover, the relative risk for minor complications, for
example gastric ulcers and erosions is significantly higher
(70.06 %) but mortality rate is low (70.09 %) [1].
In the last few years some anecdotical data suggested
that protein-sparing modified diet (PSMF) delivered by
naso-gastric tube enteral (with continuous feeding) (Pro-
MoFasT) for 15–21 days could obtain an important weight
loss and control of appetite vs delivering by mouth but no
controlled studies have demonstrated that this treatment could
be safer or more efficient than protein sparing by mouth.
In fact, there are evidences suggesting the efficacy of
protein-sparing modified fast (PSMF) in provoking a signifi-
cant weight loss associated with a high loss of body fat [2].
This formula was developed in 1970 by a work group headed
by Bistrian et al. [3] and it consists in the administration of
high biological value protein (1.2–1.4 g/kg per day), carbo-
hydrates = 40 g and vitamins and mineral supplement.
Recently, a very interesting study by Marseet-Baglieri
et al. on rats have clearly shown that in the total absence of
carbohydrates, the reduced insulin response tips the bal-
ance in favor of oxidation of lipids rather than depositing
them by means of the inhibition of triglyceride synthesis
and activation of triglyceride lipase by glucagon. Confir-
mation is provided by the fact that an increased calorie
intake and adiposity is greater in rats given a free diet with
30 % of lipids and 56 % of carbohydrates compared to
those undergoing a free diet with 50 or 70 % lipids without
carbohydrates [4].
Moreover, it has been hypothesized that tube feeding
could favor appetite control because there is evidence in
support of the anorexigenic effect induced by naso-gastric
tube feeding [5].
Even if PSMF, under proper medical supervision, can
achieve excellent results, this diet has never been studied,
without carbohydrate intake and without tube feeding.
Therefore, the present phase II trial has been designed to
verify the safety and efficacy of a protein-sparing modified
fast (PSMF) administered by naso-gastric tube with protein
intake 0.8–1 g/kg per day without carbohydrate intake (lower
than 1 %) and an adequate intake of vitamins, electrolytes and
fiber for 10 days, in patients with morbid obesity.
Patients and methods
A total of 26 patients were enrolled for the study. To be
included a BMI C30 kg/m2 was required. The patients
were selected among those who had not previously
responded to medical treatment and/or cognitive/behav-
ioral therapy, who were candidates for invasive treatment
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such as the gastric balloon or surgery but refused these
approaches.
Exclusion criteria were a severe grade active esophagi-
tis, voluminous hiatal hernia ([5 cm), active phase gastric
ulcer and/or duodenal ulcers, previous restrictive surgery of
the gastrointestinal tract, Crohn’s disease, cancers, eso-
phageal-gastro-duodenal hemorrhages in course or poten-
tial bleeding esophageal-gastric lesions, treatment with
NSAIDs or anticoagulants, patients with psychiatric dis-
orders or patients who are uncooperative, alcohol or drug-
dependent patients, type I diabetes, type II diabetes in
treatment with sulfonylurea, patients with liver, kidney or
multi-organ failure.
Further, patients with eating disorders (the patients have
been included only if they have undergone psychiatric
assessment) were excluded, patients with contra-indication
to enteral nutrition as chronic mechanical intestinal
obstruction or semi-obstruction, acute mesenteric ischemia
on a non-hypovolemic base, jejunal or intestinal fistulas
(output 400 mL/day), severe changes to intestinal func-
tionality secondary to enteropathy or insufficiency of the
absorbent surfaces thus preventing the maintenance of an
adequate nutritional state).
The endpoints were: body weight; BMI; body compo-
sition, abdominal circumference; Haber’s appetite test;
handgrip strength, biological tests and pulmonary function
test.
Handgrip strength (HGS)
HGS was measured by using the handy dynamometer
(JAMAR) by experienced personnel blinded to all clinical
and biochemical data of the patients. The patients were
instructed to produce as much handgrip pressure as possi-
ble by using the non-dominant hand. The measurements
were repeated three times, and the highest score was
recorded in kilograms.
BIA
A single tetrapolar BIA measurement of resistance (R) and
reactance (Xc) was taken at a fixed frequency of 50 kHz
between the right wrist and ankle (standard placement of
surface electrodes) with a body impedance analyzer (BIA
2000-S; Akern srl, Firenze) while the subjects were in a
supine position on a nonconductive surface. The determi-
nation of body composition parameters were assessed
according to the literature [6].
Lung function measurements
Inspired and expired volumes were measured by using a
mass flowmeter (CareFusion; VIASYS-SensorMedics Inc.,
Yorba Linda, CA, USA) with numerical integration of the
flow signal. Vital capacity (VC) and forced expiratory
volume in 1 s (FEV1) were measured according to the
American Thoracic Society/European Respiratory Society
(ATS/ERS) recommendations [7]. Functional residual
capacity (FRC) was measured by whole-body plethys-
mography V62J; CareFusion, VIASYS-SensorMedics Inc.)
during panting against a closed shutter at a frequency
ranging from 0.5 to slightly \1.0 Hz. Residual volume
(RV) was calculated by subtracting a linked expiratory
reserve volume (ERV) from FRC and total lung capacity
(TLC) by adding the subsequent inspiratory VC [8]. Pre-
dicted values for spirometry and lung volumes were from
Quanjer et al. [9].
Lung diffusing capacity for carbon monoxide (DLCO)
(Vmax22D; CareFusion, VIASYS-SensorMedics Inc.) was
measured according to the ATS/ERS task force [10] and
predicted values were from Cotes et al. [11].
Compliance and safety
The patients described complications and side effects of tube
feeding treatment in a diary. During the 6-h admissions in
Day Hospital and then at home (following the usual protocol
for Home enteral Nutrition), the patients were monitored for
safety (adverse events, complications physical exams).
During the first 10 days patients were monitored for the
following side effects: enteral nutrition ones (abdominal
distension and pain, diarrhea, vomiting, reflux, naso-gastric
tube obstruction, de-positioning or accidental removal of the
naso-gastric tube, others) and PSMF ones (cardiac arrhyth-
mia, ketosis, hypoglycemia, others). Patients were assessed
during initial observation and on a monthly basis.
Materials
The necessary materials has been sponsored by Nestle´
Health Science which supplied the devices and clinical
nutrition formula and protein oral feeding powder for the
artificial nutrition (Pumps; Infusion kits; Naso-gastric
tubes; Tube medication kits); Resource Instant Protein,
1 g/kg/ideal body weight with BMI = 25/day 9 10 days;
modified guar gum fiber (Optifibra), 20 g/day/
pt 9 10 days; potassium salt, 20 g/day 9 10 days; multi-
vitamin complete support (2/day 9 10 days). The Insur-
ance will be covered by the same company.
Diet-food protocol during and after ProMoFasT
During the first 10 days the patients were fed with a PSMF
treatment with the naso-gastric tube which was calculated
according to the characteristics reported in Table 1.
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The protein requirements were calculated by the fol-
lowing formula: protein = 1 g/kg ideal body weight (with
an ideal body weight calculated on BMI = 25).
For the following 20 days the patients followed a low-
calorie diet with a caloric deficit of about 10 % of their
caloric needs calculated by means of Harris–benedict for-
mula. The treatment and the diet has been given to patients
and followed at home and were explained by a dietician.
Moreover, some advice on changes in lifestyle was
suggested.
Naso-gastric tube placement and enteral nutrition
at home
The naso-gastric tube (NGT) was placed according to the
following procedure prescribed by the protocol.
After an overnight fast, an 8 French polyurethane naso-
gastric tube was placed according to best clinical practice.
This procedure took place in day-hospital (Dietetics and
Clinical Nutrition Unit of IRCCS San Martino University-
Hospital, Genoa, Italy) from March 2011 to October 2011.
During the visit, the patient was supplied with the nec-
essary material for enteral nutrition, a pump and enteral
feeding controllers and they received a technical explana-
tion regarding the use of the pump and any possible side
effects (see informed consent).
Patients were managed at home after training as usual
and routinely during ProMoFasT carried out at home by
our hospital in accordance with the protocol.
Patients were supplied with a free-phone number for any
technical problems related to the pump, the telephone
number of the Hospital Unit during working hours (8 am–3
pm) and a telephone number for the head of the department
for clinical problems arising outside working hours.
After 10 days the tube were removed and enteral
nutrition stopped.
Ethics
The Ethics Committee for Medical Research in Genoa,
Italy (n.reg CEA 125/10) approved the protocol in Febru-
ary 2011. The treatment followed was in accordance with
the ethical standards of the Helsinki Declaration (1975,
revised in 1983). Patients signed the informed consent
before entering to the study.
Statistical methods
Normality of distribution of measurements was assessed by
mean of histograms, Skewness index and Shapiro–Wilk
test for normality [12].
The global change of each clinical characteristic on first
30 days was separately investigated by linear mixed model
(LMM) in which time was considered as fixed factor and
the patient identifier as random effect. For spirometric
characteristics paired samples Student’s t test was used to
assess differences between baseline and 10 days.
A p of 0.05 was considered statistically significant.
SPSS (IBM Corp, v.19) was used for computation.
Results
After the recruiting phase a total of 22 patients out of 26
enrolled, with 14 females (63.6 %), were evaluated in this
study. The basal characteristics of patients are reported in
Table 2.
Three patients (9 %) dropped out during the tube feed-
ing period due to scarce compliance and 1 (3 %) for allergy
to milk protein.
Total body weight significantly decreased after 10 days
(D -6.1 ± 2; p \ 0.001) and this decrease is maintained in
the following 20 days of LCD (D = -5.88 ± 1.79;
p \ 0.001).
Also the abdominal circumference significantly
decreased after 10 days [median (range) -4.5 (-30 to 0);
p \ 0.001] and this decrease is maintained in the following
20 days of LCD [median (range) = -7 (-23.5 to -2);
p \ 0.001].
Table 1 Nutrient requirements
Nutrients Requirements/pro kg/day









Vit A (retinol) (UI/lg) 3,300
Vit D2 (UI/lg) 200
Vit E (tocopherol) (UI/mg) 10
Vit C (ascorbic acid) (mg) 60
Vit B1 (thiamine) (mg) 1.4
Vit B2 (riboflavin) (mg) 1.6
Vit B6 (pyridoxine) (mg) 2
Vit B12 (cyanocobalamin) (lg) 2
Vit B5 (pantothenic acid) (mg) 6
Vit H (biotin) (lg) 0.15
Vit PP (niacin) (lg) 18
Folic acid (lg) 200
Vit K (lg) 70
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All BIA parameters had a significant change in first
30 days from baseline (Table 3). All parameters except BF
had a significant change after 10 days of treatment while
the difference at 30 days was lower than at 10 days for
TBW, FFM and MM with no significant differences from
baseline for the last two characteristics. For VAS appetite
the difference was significant after 10 days and the
decrease in appetite was maintained at 30 days with no
significant difference (p = 0.83) between 10 and 30 days.
No significant differences in the first 30 days were detected
for PA and for both left and right hand grip strength.
Particularly, a significant FFM reduction of 1.82 kg
after 10 days was observed while not significant changes
were detected after 30 days. In contrast, a decrease of
3.8 kg of BF is observed after 30 days.
Table 4 shows the mean values for characteristics of
pulmonary function test at baseline and after 10 days of
treatment.
A statistically significant difference at 10 days was
globally observed for FRC (p = 0.013) and ERV
(p = 0.0254) with an increase of measured values.
A decrease was also observed for values of BMI with a
similar trend for time (p \ 0.001) as found for weight. In
Table 5 the biochemical data are shown.
Discussion
Body composition and metabolic parameters
The actual experience demonstrates that PSMF with naso-
gastric tube (ProMoFasT) is associated with weight
reduction mostly due to fat reduction than fat free mass.
In fact, after the first 10 days, TBW, FFM and BCM are
strongly reduced while BF is not decreased, after 20 days
of LCD the results are completely different and the BF is
strongly decreased while TBW, FFM, BCM are less
decreased. These results could depend on the variation of
the hydration during the first 10 days and after the rehy-
dration in the following 20 days.
Before weight loss, FFM hydration is usually high and
overweight and obese individuals are usually overhydrated
based on chemical cadaver analysis [13, 14].
After 10 days of ProMoFasT the patients are dehydrated
and according to the literature BIA underestimated the
changes in BF [15–17]. Finally, after 20 days of well-bal-
anced low-calorie diet the hydration is quite restored and
the measurements could be compared with the baseline.
Therefore, this could explain why the differences in
delta BF and delta BF % are not observed after 10 days but
only after 30 days.
In 2004 Buchholz and Schoeller posed serious questions
regarding the substantial difference observed in terms of
weight loss when comparing low-calorie, low-sugar and
low-fat diets. Even though the authors concluded that from
a physical point of view, a calorie is a calorie; they how-
ever highlighted that the factors adopted by Atwater in his
experiments to calculate energy that can be metabolized by
food were not exact, in so far as, this equation tends to
over-estimate the amount of available energy and fails to
take into account various factors which depend on the types
of food, such as bio-availability, type of fiber, the level of
intestinal absorption, etc. [18]. The authors further noted
that the substitution of one macronutrient with another is
not a perfectly identical phenomenon in terms of energy
results [18].
This difference can be seen in high-protein low-carbo-
hydrate diets which produce a superior weight loss of
2.5 kg after 12 weeks of treatment compared to high-pro-
tein diets alone.
In fact the authors concluded that this axiom is not
unquestionable and empiric reality demonstrates that low-
carbohydrate diets produce a greater consumption of body
fat, even though the reason for this is unclear [18].
Table 2 Clinical characteristics at baseline
Clinical characteristics Mean (SD)
Weight (kg) 120.67 (25.34)
Height (cm) 157.92 (35.83)
BMI (kg/m2) 43.98 (7.97)
Age 48.64 (10.10)
Abdominal circumference (cm) 127.08 (12.96)
VAS appetite 6.95 (1.42)
RZ (X) 396.14 (91.98)
XC (X) 49.23 (9.18)
PA () 7.21 (1.15)
TBW (kg) 52.70 (14.54)
TbW (%) 43.26 (5.88)
ICW (kg) 30.70 (9.70)
ICW (%) 58.17 (5.37)
FFM (kg) 70.89 (19.81)
FFM (%) 58.55 (8.08)
MM (kg) 50.60 (15.16)
MM (%) 41.86 (7.08)
ECM (kg) 29.07 (7.29)
BCM (kg) 42.12 (13.08)
BCM (%) 58.95 (4.58)
FM (kg) 49.81 (13.48)
FM (%) 41.52 (8.27)
Hand grip strength (right) 36.00 (13.96)
Hand grip strength (left) 32.24 (11.84)
Rz resistance, Xc reactance, PA phase angle, TBW total body water,
ICW intracellular water, FFM fat free mass, MM muscle mass, ECM
extracellular mass, BCM body cell mass, FM fat mass, SD standard
deviation
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In this regard a meta-analysis by Krieger et al. demon-
strated how a low-carbohydrate high-protein diet (protein
intake [1.05 g/kg/day–carbohydrate intake \35 % gain)
has a positive effect on body mass and its composition
irrespective of energy intake. From this meta-regression the
authors concluded that the loss of body fat is optimal when
carbohydrate intake is\41.4 % and protein intake equal to
1.20 g/kg/day [19]. On the other hand, the lost of fat free
mass following a diet seems to be independent of the total
calorie intake but only dependent on daily protein intake.
The data from the present study go further and clearly
demonstrated that the hypothesis which a complete PSMF
carbohydrate free could be associated with an important
decrease of FFM is not true.
As a matter of fact there are literature reports on similar
reduction of fat free mass after 4 weeks (as in the present
experience) of diet different in nutrient composition, i.e.,
Roy et al. after a 2,023 kcal/daily hypoglycemic diet
(43.1 % CHO) show a total weight decrease of
1.8 ± 0.5 kg, with a FFM decrease of 1.0 kg ± 2. and of
FM % 0.4 ± 6.8; Rumpler et al. after a 1,544 kcal/day
hypoglycemic diet (46 % CHO) a total weight decrease of
-5.2 kg ± 1.2 with a FFM decrease of -1.3 ± 1.9 kg and
of FM % -2.5 ± 1.3 FFT -3.9 kg ± 1.0 and Hoeger
et al. after a 1,448 kcal/hypolipidemic diet (65 % CHO) a
total weight decrease of -2.8 ± 3.4 kg with a FFM
decrease of 0.7 kg ± 1.9 and of FM % -1.2 ± 1.1 [20–
22].
Finally, a confirmation of the fat free mass maintenance
is obtained by the observation that hand grip strength in
unchanged after 10 days of ProMoFasT. HGS is an easy,
quick, inexpensive and readily available bedside test. Pre-
vious study reported that HGS may be an indirect marker
Table 3 Change of body composition at 10 and 30 days from baseline





(p value)N Mean (SD)/median
(range)








19 -4.5 (-30 to 0) \0.001 17 -7 (-23.5 to
-2)
\0.001 0.006 \0.001
TBW (kg) 19 -4.3 (3.8) \0.001 17 -1.84 (2.64) 0.012 0.016 \0.001
FFM (kg) 20 -5.9 (5.1) \0.001 18 -1.82 (4.37) 0.058* 0.014 \0.001
BCM (kg) 20 -4.7 (5.4) \0.001 18 -1 (6.48) 0.53* 0.056* 0.002
BF (kg) 20 -2 (-10 to 17.6) 0.10* 18 -4.8 (-16.4
to 5.8)
\0.001 0.002 0.002
VAS appetite 21 -2 (-7.5 to 0) \0.001 20 -2 (-8 to 0) 0.001 0.83* \0.001
Phase angle () 20 -0.4 (1.4) 18 0 (1.82) – – 0.88
Hand grip strength
Right 17 -1 (-3 to 6) – 16 -1.5 (-9 to 25) – – 0.20
Left 17 0 (-8 to 4) – 16 0.78 (-6 to 27) – – 0.98
SD standard deviation
Table 4 Standard lung function data obtained before and after
10 days of enteral protein tube feeding

















































Data are expressed as absolute numbers or means (SD) of % pre-
dicted values
VC vital capacity, FEV1 forced expiratory volume in 1 s, TLC total
lung capacity, FRC functional residual capacity, RV residual volume,
ERV expiratory reserve volume, DLCO single-breath diffusing
capacity of the lung for carbon monoxide, VA alveolar volume
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of body lean muscle mass and represents a surrogate
method to evaluate it [23].
The data obtained by the present experience are the clinical
demonstration of what obtained in the rat when carbohydrates
are absent [4]. According to Marsset-Baglieri [4] experience,
it is also possible that the complete absence of carbohydrate
may have reduced insulin secretion and thus favored the uti-
lization rather than the storage of ingested lipids.
In other words, low-carbohydrate rather than high-
protein diets may be the main factor responsible for
reducing adiposity when the protein content of the diet is
increased. Moreover, the lowered insulin secretion result-
ing from the absence of carbohydrate in diet can determine
less postprandial fat deposition [24].
In the present experience, after 1 month, insulinemia
significantly reduced and this is in agreement with a
reduced fat synthesis. In this situation of severe energy
restriction, subjects are constantly in a state of negative
energy balance, i.e., no net lipid storage occurs [4].
When analyzing the metabolism during fasting it is
important to understand which energetic substrates can be
used in a low-carbohydrate ketogenic diet.
When exogenous glucose is scarcely available and
hepatic glycogen reserves have been depleted, the body’s
physiological response is to utilize amino acids and fats in
order to produce energy and glucose.
In order to meet energetic requirements during fasting,
ketone bodies derived from the oxidation of fatty acids are
mainly used. Among the tissues that can utilize this source
of energy are: the heart, skeletal muscle, the kidneys and
mammary glands during breast feeding.
Ketone bodies are used inside the mitochondria; there-
fore, cells that do not have them, i.e., erythrocytes and the
retina cannot draw energy from them. Nevertheless, even
the brain, which uses glucose as its main fuel, can adapt to
using ketone bodies after more than 20 days of fasting. In
fact, ketone bodies different from fatty acids can, given
their hydrosolubility, overcome the haemato-encephalic
barrier. Furthermore, apart from extreme and prolonged
conditions, the central nervous system exclusively utilizes
glucose, on average 120 g per day, which it must extract
from circulating blood as it is impossible to accumulate a
reserve.
Moreover, during prolonged fasting or a low-carbohy-
drate ketogenic diet (LCKD), compensatory gluconeoge-
netic mechanisms are set in motion.
The most well-known response to this requirement is
gluconeogenesis from amino acids which permits in the
initial phase of fasting to maintain baseline glucose thanks
to the breakdown of lean muscular mass.
It is proven that the contribution of gluconeogenesis to
the production of glucose goes from 47 ± 4 % after 14 h,
67 ± 4 % after 22 h, and 93 ± 2 % after 42 h of fasting
[25].
This process is antagonized in the presence of food-
derived protein, in PSMF, which are partly used for glu-
coneogenesis and partly for endogenous protein synthesis.
Moreover, in parallel to amino acids and lactate another
important substrate exists for glucogenesis which is often
forgotten, that is glycerol coming from triglycerides. Dur-
ing prolonged fasting, 10 % of gluconeogenesis is repre-
sented by lipolysis of triglycerides with a very low
Table 5 Biochemical
modification at 30 days from
baseline
SD standard deviation
Clinical characteristics Baseline, mean (SD) 30 days, mean (SD) p value
Glucose (mg/dL) 106.71 (29.26) 95.29 (24.18) 0.002
Insulin (mU/L) 21.96 (10.26) 11.37 (4.91) \0.0011
Homa 5.58 (2.10) 2.74 (1.53) \0.001
Creatinine (mg/dL) 0.86 (0.17) 0.86 (0.19) 0.74
GGT (U/L) 22.40 (12.26) 17.43 (5.77) 0.006
ALP (U/L) 190.57 (65.61) 66.43 (15.99) \0.001
AST (U/L) 18.60 (6.69) 19.86 (3.13) 0.72
ALT (U/L) 24.20 (14.04) 21.14 (6.31) 0.28
Cholesterol (mg/dL) 256.50 (28.97) 243.3 (30.14) 0.033
Hdl (mg/dL) 50.67 (11.93) 54.00 (9.98) 0.07
Ldl (mg/dL) 127.83 (46.15) 104.00 (35.32) 0.056
Triglycerides 125.43 (60.93) 87.57 (44.09) \0.001
Na (mEq/L) 141.67 (2.80) 140.57 (2.37) 0.28
K (mEq/L) 3.90 (0.36) 3.80 (0.50) 0.43
Cl (mEq/L) 104.00 (3.11) 101.86 (4.30) 0.10
Ca (mEq/L) 9.51 (0.34) 9.44 (1.02) 0.72
P (mEq/L) 3.01 (0.28) 3.10 (0.47) 0.99
Mg (mEq/L) 1.91 (0.22) 1.94 (0.21) 0.66
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efficiency equal to 5 %; consequently, from 80 g of tri-
glycerides 8 g of glycerol and 4 g of glucose are formed.
For this reason, by not introducing carbohydrates into a
diet 1,000 g of fat allow for the production of 50 g of
glucose (the minimum quantity sufficient in preventing
lipolysis and ketogenesis) which corresponds to a caloric
intake of 9,000 kcal [26]. The contribution of glycerol to
glucose synthesis as been estimated at around 3 % after
nocturnal fasting [27] and 10 % after 60 h of fasting [28].
We can reasonably estimate that with a TEE equal to
2,000 kcal, 10 % of energy expenditure is derived from
glucose originating from glycerol that is approximately
50 g which in turn are derived from the breakdown of
1,000 triglycerides/day.
The breakdown of triglycerides in order to supply
glycerol is an extremely costly process from a thermody-
namic point of view and could in part explain the differ-
ence in weight loss achieved in patients following a
rigorous low-carbohydrate diet compared to those follow-
ing a low-protein one.
Furthermore, this phenomenon could be predominant in
the obese population.
As previously reported, the obese tend to lose less lean
mass compared to slim subjects when fasting, perhaps
because of an inferior mitochondrial efficiency which in
turn imposes a greater quantity of ketone bodies in circu-
lation consequent to a superior concentration of circulating
fatty acids [29].
From several studies including the Elia’s [30], we note
that the effects of fasting vary among lean and obese
subjects: first of all, the concentration of ketone bodies,
during the first 3 days of fasting are doubled in lean sub-
jects compared to obese ones. The ratio between
3-hydroxybutyrate and acetoacetate which is an index of
the status of mitochondrial redox increases more rapidly in
the lean compared to the obese; and finally after 60 h of
fasting, oxidation of leucine increases more significantly in
lean subjects.
To further confirm the previous data, Benedict’s his-
torical data and more recent data from Elia and Forbes’
group, during a restrictive diet obese subjects lose, a pro-
portionally inferior quantity of lean mass compared to lean
subjects [31].
Therefore, if individual genetic characters determine the
maintenance of fat free mass, it is also true that the relationship
between macronutrients influences this process [32].
As far as the metabolic parameters are concerned, after
4 weeks fasting glucose [106.71 ± 29.26 vs 95.29 ±
24.18 mg/dL (p = 0.001534)]; and insulin (from
21.96 ± 10.26 to 11.37 ± 4.91 mU/L) (p = 0.000726) are
significant statistically reduced while hyperinsulinism is
reverted (HOMA: 5.58 ± 2.10 vs 2.74 ± 1.53; p =
0.000165).
A light degree of biochemical cholestasis demonstrated
by high elevated values of ALP probably due to metabolic
syndrome steatosis, is reduced after the treatment
[190.57 ± 65.61 vs 66.43 ± 15.99 U/L (p = 0.000002)].
Hyperlipemia, frequently associated with obesity, is
observed and there is a reduction of total cholesterol
256.50 ± 28.97 vs 243.3 ± 30.14 mg/dL (p = 0.033242)
and triglycerides 125.43 ± 60.93 vs 87.57 ± 44.09 mg/dL
(p = 0.000012) following ProMoFasT.
These data are, in the short term, in agreement with
previous experiences with PSMF with an elemental diet
(protein 78 %, carbohydrates 19.6, fats 2.6 %) even if not
completely a glucidic in a short preoperative treatment with
a similar formula assumed by mouth [33].
Appetite
With regard to appetite, our data confirm the anorexigenic
effect of the ketogenic diet, but it is possible that the naso-
gastric tube feeding could play a role, too.
It is clear, however, from the available literature that a
loss of appetite can be observed when the concentration of
ketones is[4 mmol/L [34, 35] and this was observed in all
the treated patients. But, according to Rolls and Roe [5] it
has been demonstrated, under experimental conditions, that
subjects with a naso-gastric tube ingest less food and
reduce the contribution of food compared to those without
a tube even if the infusion is simulated (that is, in patients
who have a tube to which the infusion mixture is simu-
lated) compared to those in the control group who are
without a tube [5].
According to the present experience, appetite was
completely suppressed during tube feeding since the first
2 days which is different from the literature data which
show that it needs 48–72 h to enter in ketogenic state
following a PSMF with the consequent appetite suppres-
sion [34, 35].
Pulmonary function test
In the present experience, a clear benefit for lung function
has been demonstrated. As a matter of fact, the respiratory
function test FRC and ERV (espiratory reserve volume
significantly improved after only 10 days of PSMF by tube,
demonstrating the efficacy of this regime in improving the
respiratory muscle contraction in the short period. In the
literature, the most striking effect of weight loss in morbid
obesity has been the increase in lung volumes, particularly
in ERV or FRC. Several studies have reported a significant
increase in maximal voluntary ventilation (MVV). Anyway
the changes in FRC reflect changes in ERV and the
improvement in oxygenation is assumed to result from the
increase in ERV.
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Various authors report important % increase of ERV
from the baseline, but these data are significant particularly
following important weight reduction. (ERV ?157 % from
the baseline after BMI decrease from 49 to 33,7; ERV:
?65 % after BMI decrease from 42.1 to 30.9 and ERV
?48 % after BMI decrease from 56.7 to 37.4) [36–38].
Functional residual capacity is the volume of air in the
lungs at the end of a normal expiration when all respiratory
muscles are relaxed. It physiologically represents the most
important lung volume, because it approximates the level
of normal breathing. The forces of elastic movement of the
chest wall, directed outwards, tend to increase the lung
volume, but are balanced by the forces of elastic movement
of the lungs, directed inwards, which tend to reduce it.
These forces are normally equal and opposite to a lung
volume equal to about 40 % of TLC. The fast improvement
of the FRC demonstrate a good response to PSMF on
restrictive lung process due to obesity and is mainly due to
the improvement of the ERV because it represents the
volume of air remaining in the lungs at the end of a
maximal exhalation (ERV = FRC - RV). Typically, the
anomalous characteristic of obesity is a reduced ERV, due
to a marked reduction of FRC with a relatively well pre-
served RV.
The effect of rapid weight loss on pulmonary gas
exchange has been evaluated mostly in post-bariatric sur-
gery, in particular, according to Zavorsky and Hoffman
[39] over 14 studies based on 288 subjects (age 37 years,
BMI 45 kg m2).
Post-surgical data were measured up to 18.1 months
(mean range = 2.5–47 months). Mean pre- and post-
weight was 145 and 101 kg, respectively. The mean weight
loss was 45 kg (mean range was from -21 to -62 kg)
with a loss in BMI by 13 kg m2 (mean range = -7 to
-24 kg m2) at 18.1 months post-operation, improvement
in respiratory status was documented, with an increase in
PaO2 by 10 mmHg (mean range = 1–23 mmHg), a
reduction in AaDO2 by 8 mmHg (mean range = -3 to
-16 mmHg) and PaCO2 by -3 mmHg (mean range = 3
to -14 mmHg) [39].
In previous experiences weight loss improved lung
function and oxygenation in obesity.
According to Hakala a marked rise in FRC and ERV
with weight loss from 0.47 to 1.15 (p \ 0.01) is observed
after 6 weeks of very-low-calorie diet (VLCD) and
behavioral intervention in morbid obesity with VLCD
[Dietta Mini@ (MediFood, Finland)] composed of
2,100 kJ/day (500 kcal/day) (35 % protein, 1.8 % fat,
47 % carbohydrate) with 100 % of the recommended daily
allowance of vitamins and minerals [40, 41]. A statistically
significant improvement of lung function (PEF, FEV1, and
FVC) has been observed also in obese asthma patients,
before and after a VLCD period of 8 weeks [42].
The most significant improvement in lung volumes was
the increase in ERV from 0.43 to 0.72 L. The rise in ERV
also mainly accounts for the increase in FRC, because RV
did not change [43].
Aaron et al. [44] after an average loss of 20 kg over a
6-month period, observed that, for every 10 % relative loss
of weight, the FVC improved by 92 mL (p \ 0.05) and the
FEV1 improved by 73 mL (p \ 0.04). Patients who lost
[13 % of their pretreatment weight experienced
improvements in FEV1 (p \ 0.01), FVC (p \ 0.02), and
total lung capacity (p \ 0.05) compared to patients in the
lowest quartile who failed to lose significant amounts of
weight. In the present experience, the PSMF without car-
bohydrates and lipids provokes a significant improvement
of the PFT in a very short period after 10 days of weight
reduction demonstrating how far this could influence lung
function also when exogenous energy is completely
reduced with comparable results to that of a post-bariatric
surgery treatment. If we consider that there is a significant
association between handgrip strength and FVC suggesting
a further association between FVC and FFM, given that
muscle tissue mass is counted in the FFM compartment, the
maintenance of hand grip strength in our studied popula-
tion suggest that the Respiratory muscle performance
(muscle strength and endurance), could be improved after
ProMoFastT.
Enteral feeding or PSMF complications and side effects
There are no reported major complications and side effects
resulting from the enteral nutrition in any patient. In par-
ticular, no cardiac arrhythmias have been reported, nor
diarrhea nor cramps.
Constipation (3/22; 13.6 %) instead of fiber treatment,
dizziness or headache during the first 2 days [20/22;
90.9 % (only two needed medication)], general weakness
(3/22; 13,6 %), halitosis (5/22; 22,7 %) controlled by
sugarless mint chewing-gum. The naso-gastric tube was
blocked in 3 patients and required repositioning.
Most of the people felt very well and full of energy
compared with the period before.
As a matter of fact in the past, with PSMF have been
described ventricular arrhythmias, which might lead to
death [45, 46]. A correct analysis of these old data dem-
onstrated that almost all of those patients were using
hydrolyzed collagen as a protein source and were not
taking vitamin and mineral supplements [45]. Other
investigators reported arrhythmias in a prospective study of
patients using hydrolyzed collagen without adequate vita-
min and mineral intakes [46].
Hydrolyzed collagen is very poor quality protein, and
some investigators suspect that there could be cardiotoxins
in this hydrolysate of leftover, nonedible animal parts
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(tendons, ligaments, hide, etc.). In particular, recent stud-
ies, using PSMF with high-quality protein and RDA levels
of vitamins and minerals have not shown arrhythmias on
repeated 24-h electrocardiographic (Holter) monitoring
[45, 47]. In the present experience, high-quality casein was
used (resource instant protein Nestle´ Health Science).
All the patients had a slight physiologic ketosis during
the 10 days ProMoFasT.
As far as ketosis is concerned, it is important to
underline the difference between diabetes and fasting. The
two conditions are opposite: in diabetes ‘‘fuel’’ is present,
i.e., glucose and what is missing is the ‘‘access key’’ to the
cells or rather insulin; while in fasting the situation is the
opposite.
Therefore, even though during fasting the counter-reg-
ulatory hormones are more active, insulin is still present.
Conclusions
The analysis of the obtained data shows that the method of
enteral feeding with protein-sparing modified fast ready in
enteral formulation by tube) (ProMoFasT)over the 24 h has
got no side effects and it is well tolerated by patients;
therefore, it is safe and acceptable. After 10 days of
treatment there is a significant weight loss which is main-
tained for 30 days, after 20 days of a balanced mildly
reduced calorie diet. Body composition measured through
bioimpedance methodical, reveal a significant decrease of
fat free mass after 10 days which can be interpreted by a
hydration increase immediately followed by a rapid
increase in fat free mass after 20 days of hypocaloric well-
balanced diet. Regarding the analysis of the VAS appetite,
there is a significant reduction at 10 days, with a more
marked reduction after 30 days. With regard to pulmonary
function tests, contrary to what was expected, there is not
only a failure to reduced lung function or a simple main-
tenance, but also a substantial improvement shown by the
significant difference in FRC before and after 10 days and
the ERV (respiratory reserve volume) in both groups sug-
gesting a significant improvement of respiratory function
demonstrated for the first time after 10 days of PSMF with
or without tube.
The trend to improvement of hand grip strength observed,
which is positively correlated, in literature, to respiratory
muscle performance (muscle strength and endurance), sug-
gests that the PSMF with naso-gastric tube could determine a
fast respiratory benefit in the obese patient. The absence of
complications and side effects and the maintenance of fat free
mass let us make some considerations about the correct pro-
tocol which must be followed. From the nutritional point of
view, it is mandatory to administer an amount of proteins
equal to 1.2 g/kg/day with adequate vitamin (RDA),
electrolyte (RDA) and fibers (20 g/day) support. In conclu-
sion, from the clinical point of view the ProMoFasT method
appears safe and associated with significant weight loss rela-
ted to decrease of fat mass and appetite.
Therefore, this method could be considered a valuable
alternative to other methods, such as the intragastric bal-
loon, which have much more complications and side
effects. The current pilot study suggests on one hand to
implement the size of the sample by a randomized multi-
center trial, and, on the other hand, to develop additional
studies that analyze the enterohormonal response during
treatment with tube and infusion on 24 h. In the light of the
obtained results, possible clinical research field for the
method could be the pre-operative bariatric, gynecological
orthopedics and lymphatic surgery. Finally, it is crucial to
note that proponents of treatment with ProMoFasT must
possess appropriate skills in terms of:
– Experience in the diagnostic and therapeutic manage-
ment of obesity;
– Experience in artificial nutrition;
– Organization of the home enteral nutrition with a
standardized method with clear paths and management
of potential complications;
– Taking care of the subjects in a multidisciplinary
organization and therapeutic rehabilitation.
It is well known that the treatment of obesity needs
long-term management consisting of a multidisciplinary
therapeutic path in which the changes in lifestyle,
throughout diet, physical activity and behavioral treatment
could lead to concrete results which could be stable espe-
cially in maintenance.
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